Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial

Anti-Thymocyte Globulin for Patients Undergoing Hematopoietic Cell Transplantation from Unrelated Donors: A Randomized, Controlled, Open-Label, Phase 3, Multicentre Trial from Cell Therapy Transplant Canada

SSRN Electronic Journal ◽

10.2139/ssrn.3429920 ◽

2019 ◽

Author(s):

Irwin Walker ◽

Tony Panzarella ◽

Stephen Couban ◽

Felix Couture ◽

Gerald Devins ◽

...

Keyword(s):

Cell Therapy ◽

Cell Transplantation ◽

Multicentre Trial ◽

Hematopoietic Cell Transplantation ◽

Hematopoietic Cell ◽

Open Label ◽

Phase 3 ◽

Randomized Controlled ◽

Open Label Phase ◽

Unrelated Donors

Faculty Opinions recommendation of Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): a multicentre, open-label, phase 3, randomised controlled superiority trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.736675072.793566801 ◽

2019 ◽

Author(s):

Pedro Legua Leiva

Keyword(s):

Single Dose ◽

Multiple Dose ◽

Strongyloides Stercoralis ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Superiority Trial ◽

Upfront FOLFOXIRI Plus Bevacizumab and Reintroduction after Progression versus mFOLFOX6 Plus Bevacizumab Followed by FOLFIRI Plus Bevacizumab in the Treatment of Patients with Metastatic Colorectal Cancer (TRIBE2): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial by GONO

SSRN Electronic Journal ◽

10.2139/ssrn.3478102 ◽

2019 ◽

Author(s):

Chiara Cremolini ◽

Carlotta Antoniotti ◽

Daniele Rossini ◽

Sara Lonardi ◽

Fotios Loupakis ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(19)30723-8 ◽

2019 ◽

Vol 393 (10189) ◽

pp. 2404-2415 ◽

Cited By ~ 233

Author(s):

Brian I Rini ◽

Thomas Powles ◽

Michael B Atkins ◽

Bernard Escudier ◽

David F McDermott ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

Renal Cell ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30339-x ◽

2017 ◽

Vol 18 (7) ◽

pp. 874-886 ◽

Cited By ~ 216

Author(s):

Alice T Shaw ◽

Tae Min Kim ◽

Lucio Crinò ◽

Cesare Gridelli ◽

Katsuyuki Kiura ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(19)30150-0 ◽

2019 ◽

Vol 20 (7) ◽

pp. 984-997 ◽

Cited By ~ 79

Author(s):

Jorge E Cortes ◽

Samer Khaled ◽

Giovanni Martinelli ◽

Alexander E Perl ◽

Siddhartha Ganguly ◽

...

Keyword(s):

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Salvage Chemotherapy ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Randomised Controlled ◽

Acute Myeloid

Cryotherapy as prophylaxis against oral mucositis after high-dose melphalan and autologous stem cell transplantation for myeloma: a randomised, open-label, phase 3, non-inferiority trial

Bone Marrow Transplantation ◽

10.1038/s41409-019-0468-6 ◽

2019 ◽

Vol 54 (9) ◽

pp. 1482-1488 ◽

Cited By ~ 2

Author(s):

Jan-Erik Johansson ◽

John Bratel ◽

Mats Hardling ◽

Lena Heikki ◽

Ulf-Henrik Mellqvist ◽

...

Keyword(s):

Stem Cell ◽

Stem Cell Transplantation ◽

Cell Transplantation ◽

Autologous Stem Cell Transplantation ◽

Oral Mucositis ◽

High Dose ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

High Dose Melphalan

Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): a multicentre, open-label, phase 3, randomised controlled superiority trial

The Lancet Infectious Diseases ◽

10.1016/s1473-3099(19)30289-0 ◽

2019 ◽

Vol 19 (11) ◽

pp. 1181-1190 ◽

Cited By ~ 27

Author(s):

Dora Buonfrate ◽

Joaquin Salas-Coronas ◽

José Muñoz ◽

Begoña Trevino Maruri ◽

Paola Rodari ◽

...

Keyword(s):

Single Dose ◽

Multiple Dose ◽

Strongyloides Stercoralis ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Superiority Trial ◽

Safety and effectiveness of intravenous iron sucrose versus standard oral iron therapy in pregnant women with moderate-to-severe anaemia in India: a multicentre, open-label, phase 3, randomised, controlled trial

The Lancet Global Health ◽

10.1016/s2214-109x(19)30427-9 ◽

2019 ◽

Vol 7 (12) ◽

pp. e1706-e1716 ◽

Cited By ~ 6

Author(s):

Sutapa B Neogi ◽

Niveditha Devasenapathy ◽

Ranjana Singh ◽

Himanshu Bhushan ◽

Duru Shah ◽

...

Keyword(s):

Pregnant Women ◽

Controlled Trial ◽

Intravenous Iron ◽

Severe Anaemia ◽

Iron Sucrose ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Faculty Opinions recommendation of Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717950273.793455532 ◽

2012 ◽

Author(s):

Alexander Eggermont

Keyword(s):

Metastatic Melanoma ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽